MGF (C-terminal) 5mg

Scientists have known about alternative splicing for some time now. The process refers to the ability of a cell to create mRNA strands in different ways to produce a wide variety of proteins from the same basic DNA sequence. IGF-1 turns out to be on the extreme end of alternative splicing. With six exons and multiple transcription sites, IGF-1 can be spliced into two classes consisting of three major isoforms each (IGF-1Ea, IGF-1Eb, IGF-1Ec) for a total of at least six different proteins. These peptides can then be further modified to produce an even wider variety of alternatives^[1].

Mechano-growth factor is an alternative name for the IGF-1Eb isoform of IGF-1. It has been shown to play important roles in muscle remodeling, cellular proliferation, and cellular survival. New research suggests that this particular isoform can also activate satellite cells in skeletal muscle, proteger las neuronas, and offset the muscle-wasting effects of aging^[3].

The primary role of MGF is in muscle acute repair, particularly after exercise or injury. Research in rats shows that concentrations of MGF increase dramatically following muscle injury and that its presence in muscle correlates strongly with skeletal muscle cell growth and differentiation^[3].

MGF Levels Affected by Age

Como resulta, the specific versions of IGF-1 that are produced depends on a number of factors. Edad, steroid hormones, growth hormone, and other developmental cues all affect how IGF-1 is spliced and the final peptides that are produced. Edad, En particular, has been found to have major influence on the expression of IGF-1 isoforms. Young men show now preference between class 1 and class 2 isoforms whereas older men show a statistically and physiologically significant shift toward class 1Ea^[2]. The overall significance of this change in terms of obvious signs of aging isn’t clear, but it offers an experimental starting point for understanding better the aging process. There is some thought that MGF supplementation may be able to offset the muscle-diminishing effects associated with aging, though more research is required in this area.

Mechano-Growth Factor and Inflammation

Muscle cell regeneration is mediated by inflammatory cells and the particular signaling molecules they release. Macrophages are especially important in this process and appear to be primary producers of MGF in the setting of muscle cell inflammation. IGF-1Ea (MGF) has been shown to have anti-inflammatory effects, but also prolongs the life of macrophages. The exact significance of this effect has yet to be elucidated, but it is speculated that exogenous MGF administration may boost muscle cell healing rates by affecting macrophages^[4].

MGF Research, Muscle Growth and Optimized Physical Training

MGF has been shown to boost hypertrophy and repair of muscle by activating muscle stem cells (called satellite cells). Studies in mice show a 25% increase in mean muscle fiber size after just three weeks of intramuscular MGF injection. Researchers speculate that the peptide could be beneficial in the setting of muscle wasting diseases and that it may also be useful in boosting the effects of exercise^[5]. While that latter may seem like an odd recommendation to come from stolid researchers, it underlies the importance of muscle mass in baseline metabolism. It has long been known that boosting muscle mass is a good way to improve basal rates of metabolism and aid in weight loss and fat burning. The ability to improve lean body mass after even moderate exercise could be one part of a multi-faceted approach to the obesity epidemic and the host of medical conditions associated with overweight status.

In the setting of muscle-wasting disease, such as Duchenne muscular dystrophy (DMD), transplanting precursors of muscle cells (called myogenic precursor cells) has been shown to improve dystrophin expression and help offset the effects of some conditions. Desafortunadamente, survival rates after transplant are low and so the procedure has never been of much therapeutic value. New research in mouse models indicates that MGF can boost survival of myogenic precursor cells and may lead to enhanced transplant success^[6]. The benefit of MGF could help make myogenic precursor cell transplant a mainstay of DMD treatment whereas it was once considered a fringe, last-ditch procedure when other options had been exhausted.

Mechano-Growth Factor and Cartilage

Cartilage damage can occur as a result of injury, repetitive overuse of a joint (osteoarthritis), or inflammatory disease (p.ej. artritis reumatoide). Desafortunadamente, cartilage does not heal well for a variety of reasons including inadequate blood supply and a dearth of stem cells necessary for substantial regeneration. Research on MGF, sin embargo, indicates that the peptide might be able to help overcome some of the inherent limitations of cartilage regeneration.

It appears that MGF helps chondrocytes, the cells primarily responsible for cartilage health and regeneration, survive in response to mechanical stimuli. En otras palabras, in the setting of physical stress on cartilage, MGF boosts survival of the very cells necessary to protect against that stress and repair any damage that it causes. These effects appear to be mediated through several pathways, including the YAP signaling pathway, which boosts chondrocyte migration into cartilage^[7].

It is important to note that MGF is not just therapeutic following cartilage injury, but has been found to help prevent injury and long-term disability as well. Mechanical overload is one of the primary causes of disc degeneration in the human spine because overloading chondrocytes causes them to undergo apoptosis (muerte celular programada). Research in rodents indicates that MGF can inhibit apoptosis in the cells and thus help to prevent disc degeneration from occurring in the first place^[8]. Researchers are actively investigating the use of MGF supplementation to reduce spinal degeneration caused by mechanical overload.

MGF in Brain Development and Neuron Health

The presence of MGF in the developing brains of mice was demonstrated as far back as 2010 in research that showed the peptide to have neuroprotective effects. Subsequent studies in rodent models have shown that MGF is highly expressed in the setting of brain hypoxia and that it is overexpressed in brain regions where neuron regeneration is taking place. That the peptide has benefit in protecting neurons was finally made clear in a study using a mouse model of ALS (Lou Gehrig’s Disease). Treatment with MGF improves the overall progressive muscle weakness seen in ALS and slows the primary cause of the disease, which is loss of motor neurons^[9]. De hecho, MGF is significantly better at protecting neurons in the setting of ALS than any other IGF-1 isoform and has been found in regenerating regions of adult brains following global ischemia^[10]. There is currently hope that MGF may be used as a treatment to improve muscle function in ALS and protect motorneurons from death^[11].

Mechano-Growth Factor and Heart Cells

Research in sheep models of acute myocardial infarction (infarto de miocardio) indicates that MGF protects heart muscle against ischemia. De hecho, the study found that there is a 35% reduction in cardiomyocyte compromise following the injection of MGF and considerable benefit following heart attack^[12]. This is a substantial finding because, to date, there have been a limited number of interventions that can reduce the impact of a heart attack while it is happening. Short of stent placement or the administration of clot-busting drugs (which carry the risk of causing life-threatening bleeding), there is little that can be done during the acute stages of heart attack. Most treatment has focused instead on protecting tissue following and event and restoring as much function as possible. MGF is opening new avenues for treating acute MI that could give first responders a real tool that can reduce the impact of heart attack by more than one third. Given that cardiovascular disease is, but far, the largest killer of adults in most developed nations, this finding has the potential for substantial benefit.

MGF is being explored via a number of different research avenues. Ahora mismo, the peptide shows a great deal of promise in protecting muscle tissue of all types from a wide variety of insults. This makes MGF a prime candidate for pharmaceutical development and the peptide may serve as the basis for a number of breakthrough treatments over the next decade. Además, new aspects of MGF are being uncovered regularly. The peptide is already known to protect neurons and boost cartilage health, so there is a wide area of application for current and future research.

MGF exhibits minimal side effects, baja biodisponibilidad oral y excelente subcutánea en ratones. La dosis por kg en ratones no se aplica a los humanos. MGF for sale at

La literatura anterior fue investigada, editado y organizado por el Dr.. logan, MARYLAND. Dr. Logan tiene un doctorado de Facultad de Medicina de la Universidad Case Western Reserve y una licenciatura. en biología molecular.

Paul Goldspink, Doctor es el investigador principal y profesor asociado del Departamento de Fisiología de la Facultad de Medicina de Wisconsin.. La investigación en el Dr.. El laboratorio de Goldspink se centra en comprender las acciones de las isoformas de IGF-1 en el corazón y otros tejidos. Estamos investigando el papel de las isoformas de IGF-1 en respuesta a tensiones como la sobrecarga mecánica., hipoxia, Estrés oxidativo y edad en el corazón.. Nos hemos centrado en una isoforma particular llamada factor de crecimiento mecánico. (MGF), que juega un papel protector en la prevención de la muerte celular, Preservar la contractilidad y prevenir la hipertrofia patológica del corazón después de un infarto de miocardio.. Actualmente estamos investigando los mecanismos subyacentes que utilizan análogos peptídicos derivados de la región del dominio E de MGF que sirven como moduladores alostéricos de las vías de excitación-transcripción en el músculo.. A través de colaboraciones hemos podido explotar nuestros hallazgos mediante el desarrollo de una tecnología que combina una estructura física microscópica para administrar terapias peptídicas., con el objetivo de mejorar la función cardíaca durante la progresión de la insuficiencia cardíaca mediante el uso de "dispositivos biomiméticos" implantables del tamaño de células. El desarrollo de estas plataformas inteligentes de administración de fármacos que hemos empleado recientemente en el corazón, También tienen aplicabilidad en otros tejidos y estados patológicos..

Paul Goldspink, PhD is being referenced as one of the leading scientists involved in the research and development of MGF. De ninguna manera este médico/científico respalda o defiende la compra, venta, o uso de este producto por cualquier motivo. No hay afiliación o relación., implícito o no, entre

1. A. Philippou, METRO. Maridaki, S. Pneumaticos, y M. Koutsilieris, “The Complexity of the IGF1 Gene Splicing, Posttranslational Modification and Bioactivity,"Mol. Con., volumen. 20, No. 1, páginas. 202–214, Puede 2014.
2. A. METRO. Oberbauer, “The Regulation of IGF-1 Gene Transcription and Splicing during Development and Aging," Frente. Endocrinol., volumen. 4, Mar. 2013.
3. R. W.. Matheny, B. C. Nindl, y M. l. Adamo, “Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration,” Endocrinología, volumen. 151, No. 3, páginas. 865–875, Mar. 2010.
4. K.-T. Sol, K.-K. Cheung, S. W.. norte. au, S. S. Yeung, y E. W.. Yeung, “La sobreexpresión del factor de crecimiento mecánico modula la expresión de citoquinas inflamatorias y la resolución de macrófagos en lesiones del músculo esquelético," Frente. Fisiol., volumen. 9, 2018.
5. GRAMO. rosa dorado, “Investigación sobre el factor de crecimiento mecánico.: su potencial para optimizar el entrenamiento físico así como el uso indebido en el dopaje,Hermano. j. Medicina deportiva., volumen. 39, No. 11, páginas. 787–788, Nov. 2005.
6. PAG. Mills, j. C. Dominique, j. F. Lafrenière, METRO. Bouchentouf, y j. PAG. Tremblay, “A Synthetic Mechano Growth Factor E Peptide Enhances Myogenic Precursor Cell Transplantation Success," Soy. j. Transplant., volumen. 7, No. 10, páginas. 2247–2259, 2007.
7. incógnita. Jing et al., “El factor de crecimiento mecánico protege contra el daño inducido por sobrecarga mecánica y promueve la migración de los condrocitos de la placa de crecimiento a través de la vía RhoA/YAP,” Exp.. Resolución celular., volumen. 366, No. 2, páginas. 81–91, Puede 2018.
8. q. Xu, h. Fang, l. zhao, C. zhang, l. zhang, y B. Tian, “Mechano growth factor attenuates mechanical overload-induced nucleus pulposus cell apoptosis through inhibiting the p38 MAPK pathway,” Biosci. Reps., volumen. 39, No. 3, Mar. 2019.
9. j. Dluzniewska et al., “Un fuerte efecto neuroprotector del péptido C-terminal autónomo de IGF-1 Ec (MGF) en isquemia cerebral,” FASEB J. Apagado. público. alimentado. Soy. sociedad. Exp. Biol., volumen. 19, No. 13, páginas. 1896–1898, Nov. 2005.
10. B. Zablocka, PAG. h. rosa dorado, GRAMO. rosa dorado, y D. C. Gorecki, “Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?," Frente. Endocrinol., volumen. 3, 2012.
11. j. Riddoch-Contreras, S.-Y. Cual, j. R. t. Dick, GRAMO. rosa dorado, R. W.. Orrell, y l. Greensmith, “Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice,” Exp.. Neurol., volumen. 215, No. 2, páginas. 281–289, Feb. 2009.
12. V. Carpenter et al., “Mechano-Growth Factor Reduces Loss of Cardiac Function in Acute Myocardial Infarction,” Heart Lung Circ., volumen. 17, No. 1, páginas. 33–39, Feb. 2008.

TODOS LOS ARTÍCULOS E INFORMACIÓN DE PRODUCTOS PROPORCIONADOS EN ESTE SITIO WEB SON SÓLO PARA FINES INFORMATIVOS Y EDUCATIVOS.

Los productos ofrecidos en este sitio web se proporcionan únicamente para estudios in vitro.. Estudios in vitro (latín: en cristal) se realizan fuera del cuerpo. Estos productos no son medicamentos ni fármacos y no han sido aprobados por la FDA para prevenir, tratar o curar cualquier condición médica, dolencia o enfermedad. La introducción corporal de cualquier tipo en personas o animales está estrictamente prohibida por la ley..